Checkpoint Inhibitors Competitive Landscape Report 2026: Comprehensive Insights About 50+ Companies and 60+ Drugs
Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The report delivers extensive insights into over 50 companies and 60 drugs within the checkpoint inhibitors space. This comprehensive analysis highlights therapeutics assessment by product type, stage, route of administration, and molecule type, alongside a focus on inactive pipeline products.
Geographical Coverage: Global
Immune checkpoint inhibitors play a pivotal role in cancer treatment by enhancing the immune system's ability to target cancer cells. These inhibitors work by blocking checkpoint proteins like CTLA-4, PD-1, and PD-L1, which can prevent T cells from attacking cancer cells. The report covers inhibitors such as CTLA-4, which enhances immune responses, PD-1 inhibitors preventing immune suppression, and PD-L1 inhibitors helping the immune system recognize cancer.
Checkpoint inhibitors enhance the immune response against various cancers such as melanoma, lung cancer, and kidney cancer. However, they are not without potential side effects, as immune-related adverse events (irAEs) may occur due to heightened immune activity.
Recent advancements in checkpoint inhibitors include notable industry activities. In February 2025, Genome & Company partnered with Ellipses Pharma for GENA-104, targeting CNTN4. Helix BioPharma Corp. acquired LR 09 from Laevoroc Immunology AG in November 2024. OncoC4, Inc. dosed its first patient in ONC-841-002 trial in August 2024, evaluating ONC-841 for solid tumors. The FDA cleared OncoC4's IND application for ONC-841 in April 2024, while Mozart Therapeutics began clinical trials for MTX-101 in June 2024.
Company and Product Profiles (Marketed Therapies)
Company and Product Profiles (Pipeline Therapies)
Analytical Perspective
The report offers depth on collaborations, licensing, and acquisition trends, elaborating on company interactions and market analysis, vital for understanding the competitive landscape of checkpoint inhibitors. Detailed assessments cover therapeutic and pipeline profiles, unmet needs, and provide vital industry insights.
Key Players include CanBas Co. Ltd, Boundless Bio, OncoC4, and Transcode Therapeutics, with key products like CBP 501, BBI-355, ONC-841, and TTX siPDL1 marking advancements in the field.
Key Topics Covered:
Introduction
Executive Summary
Checkpoint Inhibitors: Overview
Checkpoint Inhibitors - Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Therapeutic Assessment
Checkpoint Inhibitors: Company and Product Profiles (Marketed Therapies)
Bristol Myers Squibb/ Ono Pharmaceuticals
Opdivo
Checkpoint Inhibitors: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
Company Name
Drug Name
Mid Stage Products (Phase II)
CanBas Co. Ltd.
CBP 501
Early Stage Products (Phase I)
OncoC4
ONC-841
Preclinical and Discovery Stage Products
Company Name
Product Name
Inactive Products
Checkpoint Inhibitors- Unmet needs
Checkpoint Inhibitors - Market drivers and barriers
Appendix
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/gg1i45
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.